Q1 Earnings Forecast for Cytokinetics Issued By B. Riley

Cytokinetics, Incorporated (NASDAQ:CYTK) – Research analysts at B. Riley issued their Q1 2026 EPS estimates for shares of Cytokinetics in a report issued on Monday, November 10th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will post earnings of ($1.62) per share for the quarter. B. Riley has a “Buy” rating and a $90.00 price target on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q2 2026 earnings at ($1.62) EPS, Q3 2026 earnings at ($1.67) EPS and Q4 2026 earnings at ($1.56) EPS.

Other research analysts have also issued research reports about the company. Stifel Nicolaus raised their price objective on Cytokinetics from $87.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Cytokinetics in a research note on Tuesday, October 21st. JMP Securities reiterated a “market outperform” rating and issued a $78.00 price objective on shares of Cytokinetics in a report on Tuesday, September 2nd. Wall Street Zen lowered Cytokinetics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Cytokinetics in a research report on Monday, September 29th. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and an average target price of $77.36.

Cytokinetics Price Performance

Shares of NASDAQ:CYTK opened at $62.20 on Tuesday. Cytokinetics has a 1 year low of $29.31 and a 1 year high of $64.13. The firm has a market capitalization of $7.60 billion, a PE ratio of -12.20 and a beta of 0.58. The business’s 50 day moving average price is $55.80 and its 200-day moving average price is $42.28.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.59) by $0.05. The company had revenue of $1.94 million for the quarter, compared to analysts’ expectations of $6.05 million. The firm’s revenue for the quarter was up 318.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.36) EPS.

Institutional Investors Weigh In On Cytokinetics

A number of institutional investors have recently modified their holdings of CYTK. State of Michigan Retirement System increased its stake in Cytokinetics by 1.1% during the first quarter. State of Michigan Retirement System now owns 28,200 shares of the biopharmaceutical company’s stock worth $1,133,000 after purchasing an additional 300 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of Cytokinetics by 0.9% in the first quarter. Louisiana State Employees Retirement System now owns 33,100 shares of the biopharmaceutical company’s stock valued at $1,330,000 after acquiring an additional 300 shares in the last quarter. Edgestream Partners L.P. acquired a new position in Cytokinetics during the 1st quarter worth $732,000. Jennison Associates LLC acquired a new stake in Cytokinetics in the 1st quarter valued at about $27,085,000. Finally, Teachers Retirement System of The State of Kentucky boosted its stake in shares of Cytokinetics by 9.6% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 60,357 shares of the biopharmaceutical company’s stock valued at $2,426,000 after buying an additional 5,282 shares during the period.

Insiders Place Their Bets

In other news, Director Edward M. Md Kaye sold 6,757 shares of the business’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $60.00, for a total value of $405,420.00. Following the sale, the director directly owned 9,778 shares of the company’s stock, valued at approximately $586,680. The trade was a 40.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert I. Blum sold 5,000 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $49.77, for a total transaction of $248,850.00. Following the transaction, the chief executive officer directly owned 373,108 shares of the company’s stock, valued at $18,569,585.16. The trade was a 1.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 56,983 shares of company stock valued at $3,165,356. 2.70% of the stock is owned by company insiders.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.